A5083766802- Multiple Myeloma Research and Treatments
- Peptidase Inhibition and Analysis
- Bone health and treatments
- Cancer, Hypoxia, and Metabolism
- Ubiquitin and proteasome pathways
- Protein Degradation and Inhibitors
- Chemokine receptors and signaling
- Bone Metabolism and Diseases
- Calcium signaling and nucleotide metabolism
- Cancer therapeutics and mechanisms
- Angiogenesis and VEGF in Cancer
- Immunotherapy and Immune Responses
- Radiopharmaceutical Chemistry and Applications
- Cell Adhesion Molecules Research
- Wnt/β-catenin signaling in development and cancer
- Blood disorders and treatments
- Adenosine and Purinergic Signaling
- Bone fractures and treatments
- Signaling Pathways in Disease
- Hepatitis B Virus Studies
- Hematological disorders and diagnostics
- Electrolyte and hormonal disorders
- Orthopedic Surgery and Rehabilitation
- Sepsis Diagnosis and Treatment
- Glycosylation and Glycoproteins Research
Hospital Universitario Rey Juan Carlos
2024
Azienda Unità Sanitaria Locale Piacenza
2021-2023
University of Parma
2010-2019
Myeloma UK
2015-2016
Ospedale di Parma
2009
Human mesenchymal stem cells (hMSCs) are pluripotent adult capable of being differentiated into osteoblasts, adipocytes, and chondrocytes. The osteogenic differentiation hMSCs is regulated either by systemic hormones or local growth factors able to induce specific intracellular signal pathways that modify the expression activity several transcription factors. Runt-related factor 2 (Runx2) Wnt signaling-related molecules major critically involved in process hMSCs, SRY-related...
Multiple myeloma (MM) derives from malignant transformation of plasma cells (PC), which accumulate in the bone marrow (BM), where microenvironment supports tumor growth and inhibits anti-tumor immune responses. Adenosine (ADO), an immunosuppressive molecule, is produced within MM patients' BM by adenosinergic ectoenzymes, starting ATP (CD39/CD73) or NAD+ [CD38/CD203a(PC-1)/CD73]. These ectoenzymes form a discontinuous network expressed different cells. We investigated expression function on...
It is known that multiple myeloma (MM) cells express CD38 and a recently developed human anti-CD38 monoclonal antibody Daratumumab mediates killing. However, the expression of other functionally related ectoenzymes within MM bone niche potential effects on are still unknown. This study firstly defines by flow cytometry immunohistochemistry marrow in cohort patients with indolent gammopathies. Results indicate only plasma expressed at high level niche. In addition, analysis shows was also...
ABSTRACT Multiple myeloma (MM) is characterized by severely imbalanced bone remodeling. In this study, we investigated the potential effect of proteasome inhibitors (PIs), a class drugs known to stimulate formation, on mechanisms involved in osteocyte death induced MM cells. First, performed histological analysis viability biopsies cohort 37 patients with symptomatic disease. A significantly higher number viable osteocytes was detected treated bortezomib (BOR)-based regimen compared those...
Bone marrow monocytes are primarily committed to osteoclast formation. It is, however, unknown whether potential primary alterations specifically present in bone from patients with multiple myeloma, smoldering myeloma or monoclonal gammopathy of undetermined significance. We analyzed the immunophenotypic and transcriptional profiles CD14+ a cohort different types gammopathies identify involved myeloma-enhanced osteoclastogenesis. The number CD14+CD16+ cells was higher active than those...
Pain assessment is essential in nursing care. The Numerical Rating Scale (NRS) widely used but may not fully capture pain's multidimensional nature. Assessment Advanced Dementia (PAINAD) scale reliable for assessing pain cognitively impaired patients. This study aims to evaluate the validity of Italian version PAINAD (PAINAD-IT) postoperative geriatric patients with femur fractures. employs PAINAD-IT, which was translated and validated context by Costardi et al. (2007). Face content (I-CVI...
The use of Lenalidomide (LEN), to reverse tumor-mediated immune suppression and amplify multiple myeloma-specific immunity is currently being explored. Particularly, LEN effects on dendritic cells (DCs) are still unclear. In this study, we investigated the potential effect DC differentiation activity. DCs were differentiated either from CD14+ obtained patients with myeloma or a human monocytic cell line. LEN, at concentration range reached in vivo, significantly increased median intensity...
C-X3-C motif chemokine ligand 1 (CX3CL1)/fractalkine is a released after cleavage by two metalloproteases, ADAM metallopeptidase domain 10 (ADAM10) and 17 (ADAM17), involved in inflammation angiogenesis the cancer microenvironment. The role of CX3CL1/ receptor 1(CX3CR1) axis multiple myeloma (MM) microenvironment still unknown. Firstly, we analyzed bone marrow (BM) plasma levels CX3CL1 111 patients with cell disorders including 70 active MM, 25 smoldering (SMM), 16 monoclonal gammopathy...